Entries by Harikesh Pushpapathan

Year in review 2023

2023 has been another big year at Stoic. We first provide commentary on the venture market this year. We then dig into what we’ve been up to in the past 12 months. Observations of the venture market There were a few narratives that dominated markets in 2023, none more so than the reversion to the ‘new normal’ […]

Year in review 2023 : Observations of the venture market

2023 has been another big year at Stoic. We first provide a commentary on the state of the markets. We then dig into what we’ve been up to in the past 12 months. Observations of the venture market There were a few narratives that dominated markets in 2023. For us it was simple — the ‘new normal’ might not […]

Stoic’s Year in review 2023

2023 has been another big year at Stoic. We first provide commentary on the venture market this year. We then dig into what we’ve been up to in the past 12 months. Observations of the venture market There were a few narratives that dominated markets in 2023, none more so than the reversion to the ‘new normal’ […]

A primer on building Neurotech — part 2

A primer on building Neurotech — part 2 In part 1 we examined product development and defensibility. In part 2, we look at product delivery and best practice strategies for regulation and reimbursement. Successful product delivery = Longitudinal (relationship with regulators + evidence generation). Note: Naturally — much of this discussion can be generalised to Medical Devices. How can I increase […]

A primer on building Neurotech — part 1

A primer on building Neurotech — part 1 The thesis for Neurotech is that by interfacing directly with the nervous system, we can more accurately map the pathophysiology of various neurological & psychiatric disorders. Not just at discrete points in time, but continuously. Biology-driven conditions like Major Depressive Disorder, Schizophrenia and Alzheimers should be measurable and conservable. i.e […]